About the ANCA-Associated Vasculitis Working Group

The methods for creating a composite outcome are different than for individual domain-directed outcomes and this Workshop will help attendees understand the steps required for this process through a project that is funded by ACR and EULAR to create response criteria for ANCA-associated vasculitis for use in clinical trials. Attendees are encouraged before the Workshop to view the short but highly informative videos developed to inform everyone on the disease under study and the methods employed for this project.

Haner_Direskeneli

Haner Direskeneli

Co-Chair

Peter Merkel

Peter Merkel

Co-Chair

gunnar

Gunnar Tómasson

Co-Chair

kaitlin quinn

Kaitlin Quinn

Fellow

Screen Shot 2021-02-17 at 11.40.13 AM

Sara Monti

Fellow

georgia lanier

Georgia Lanier

Patient Research Partner

Introduction to Antineutrophil cytoplasmic antibody ANCA-Associated Vasculitis

Introduction To Methodology To Develop A Composite Outcome Measure For ANCA-Associated Vasculitis

OMERACT Endorsed Core Set of Outcome Measures for Clinical Trials in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Screen Shot 2021-02-12 at 8.41.02 PM

Working Group Members:

Alibaz-Oner, Fatma
Aydin, Sibel
Björk, María
Cam, Esen
Christensen, Robin
Dejaco, Christian
Direskeneli, Haner
Grayson, Peter
Hatemi, Gülen

Jayne, David
Kermani, Tanaz
Langford, Carol
Lanier, Georgia
Mackie, Sarah
Mahr, Alfred
Meara, Alexa
Milman, Nataliya
Ozguler, Yesim

Pagnoux, Christian
Robson, Joanna
Shea, Beverly
Tómasson, Gunnar
Merkel, Peter
Milman, Nataliya
Monti, Sara
Quinn, Kaitlin
Tugwell, Peter

Scroll to Top